Lupus Anticoagulant and Anticardiolipin Antibodies in Serum of Patients Treated With Risperidone

View This PDF

NB: This article is only available as a PDF.

Letter to the Editor

Sir: In recent years, several studies reported an increased rate of cerebrovascular events in patients treated with risperidone. In April 2005, the U.S. Food and Drug Administration issued a health advisory warning concerning an increased risk of death among patients with dementia who were treated with atypical antipsychotic agents.

Risperidone is a second-generation antipsychotic agent that reportedly increases the blood level of glucose and alters changes in lipid profiles.

J Clin Psychiatry 2009;70(5):769-771